ArticleFuture oncology (London, England)2023

Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.

Christian Buske et al.PubMed ↗Publisher ↗

No numbers read from the abstract.